ganfeborole   Click here for help

GtoPdb Ligand ID: 12796

Synonyms: GSK3036656 | GSK656
Compound class: Synthetic organic
Comment: Ganfeborole (GSK3036656) is a first-in-class boron-containing antitubercular agent. It is the lead from a series of 3-aminomethylbenzoxaboroles that are potent inhibitors of Mycobacterium tuberculosis leucyl-tRNA synthetase (LeuRS) [2]. We show the (S) enantiomer, which is the most active form.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 84.94
Molecular weight 257.48
XLogP -0.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1=C(C2=C(C(=C1)OCCO)B(O)O[C@@H]2CN)Cl
Isomeric SMILES O(CCO)C1=C2C([C@@H](CN)OB2O)=C(Cl)C=C1
InChI InChI=1S/C10H13BClNO4/c12-6-1-2-7(16-4-3-14)10-9(6)8(5-13)17-11(10)15/h1-2,8,14-15H,3-5,13H2/t8-/m1/s1
InChI Key DJUOWOXTPXUHDQ-MRVPVSSYSA-N
No information available.
Summary of Clinical Use Click here for help
Ganfeborole is being developed by GlaxoSmithKline as a treatment for tuberculosis. First-in-human safety and pharmacokinetics were reported in 2019 [3] and a Phase 2 early bacterial activities study has been completed (NCT03557281). A Phase 2 trial of ganfeborole in combination with bedaquiline or delamanid is recruiting (NCT05382312, last update January 2023).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05382312 Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in Combination With Delamanid or Bedaquiline, Delamanid in Combination With Bedaquiline, or Standard of Care in Male and Female Participants Aged 18 to 65 Years With Pulmonary Tuberculosis Phase 2 Interventional GlaxoSmithKline
NCT03557281 An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis Phase 2 Interventional GlaxoSmithKline
NCT03075410 First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects Phase 1 Interventional GlaxoSmithKline Drug is well tolerated with no serious adverse events reported. 3